Abstract: A contact system includes a support body, a heat sink configured to contact the support body in an electrically insulated and/or heat-conducting manner, and an electrically insulating layer arranged between the heat sink and the support body. The heat sink has a first surface which is embodied substantially as a flat area and formed with a recess in a region intended for contacting a periphery of a contact area of the support body. The recess forms an unbroken track on the first surface of the heat sink. The contact area of the support body is located on the heat sink in such a way that the recess extends completely along the periphery of the contact area. The insulating layer between the heat sink and the support body is configured to cover the recess in such a way that a closed channel is formed by the recess and the insulating layer.

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat certain conditions such as addiction, alcohol dependence, opioid abuse treatment, neurological disorders, neuropathic pain, fibromyalgia, and combinations thereof. The compounds act by acting as selective antagonist to the kappa (?) opioid receptor. Further, disclosed compounds are an analog compound that can act as an antagonist to one or more opioid receptors. When present, these compounds lead to the inhibition of conditions, providing increased performance over known treatments. The disclosed compounds also shows the ability to cross the blood-brain-barrier in a highly efficient manner. The disclosed compounds are shown to be effective in the nanomolar range.

Abstract: Disclosed is a composition and method for a therapeutic treatment that is able to combat certain conditions such as addiction, alcohol dependence, opioid abuse treatment, neurological disorders, neuropathic pain, and combinations thereof. The compounds act by acting as selective antagonist to the kappa (?) opioid receptor, which, when present leads to the inhibition of conditions, providing increased performance over known treatments. The disclosed compounds also shows the ability to cross the blood-brain-barrier in a highly efficient manner. The disclosed compounds are shown to be effective in the nanomolar range.

Abstract: An animal restraining apparatus is disclosed which provides head, tail, and hind leg apertures for gaining access to an animals head, tail and perianal area, and hind legs for physiological and pharmacological studies of awake animals using direct mechanical, thermal, chemical and/or pharmacological stimuli.

Abstract: An animal restraining apparatus is disclosed which provides head, tail, and hind leg apertures for gaining access to an animals head, tail and perianal area, and hind legs for physiological and pharmacological studies of awake animals using direct mechanical, thermal, chemical and/or pharmacological stimuli.